Literature DB >> 32409349

Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease.

Sashiananthan Ganesananthan1, Dharmaraj Durai2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32409349      PMCID： PMC7243528          DOI： 10.7861/clinmed.20-2-s23

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  4 in total

Review 1.  Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.

Authors:  N S Ding; A Hart; P De Cruz
Journal:  Aliment Pharmacol Ther       Date:  2015-10-30       Impact factor: 8.171

2.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Authors:  Niels Vande Casteele; Marc Ferrante; Gert Van Assche; Vera Ballet; Griet Compernolle; Kristel Van Steen; Steven Simoens; Paul Rutgeerts; Ann Gils; Séverine Vermeire
Journal:  Gastroenterology       Date:  2015-02-24       Impact factor: 22.682

Review 3.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Authors:  Joseph D Feuerstein; Geoffrey C Nguyen; Sonia S Kupfer; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-08-03       Impact factor: 22.682

Review 4.  Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.

Authors:  Casper Steenholdt; Klaus Bendtzen; Jørn Brynskov; Mark A Ainsworth
Journal:  Inflamm Bowel Dis       Date:  2016-08       Impact factor: 5.325
  4 in total
  1 in total

Review 1.  Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review.

Authors:  Silvia Marquez-Megias; Ricardo Nalda-Molina; Javier Sanz-Valero; Patricio Más-Serrano; Marcos Diaz-Gonzalez; Maria Remedios Candela-Boix; Amelia Ramon-Lopez
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.